Trial Profile
A study to probe the safety and durability of tenofovir and a cell cycle agent to maintain viral suppression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Hydroxycarbamide (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Efavirenz; Emtricitabine; Lamivudine; Nevirapine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms HADIT
- 21 May 2010 Actual patient number added as 9 as reported by ClinicalTrials.gov.
- 26 Jun 2007 Status change from recruiting to completed.
- 04 Nov 2006 New trial record.